Key Takeaways
- Gensaic, a biotech startup, is developing AI-driven protein shuttles to deliver RNA-based therapeutics to specific body tissues.
- The company aims to transform the treatment of metabolic diseases through precise drug delivery, collaborating with firms like Novo Nordisk.
- Gensaic’s FORGE platform has screened over 500 billion proteins, focusing on complex disease systems and potentially multiplexed medicines.
Innovative Drug Delivery Method
Gensaic, founded by Lavi Erisson, Uyanga Tsedev, and Jonathan Hsu, is tackling one of the major challenges in the therapeutic sector: delivering RNA-based drugs to the right tissues. RNA treatments, while promising, are often fragile and difficult to target effectively within the body.
The startup is using an AI-powered discovery engine to create protein shuttles that deliver these vital molecules to specific cells. This innovative approach seeks to enhance treatments for metabolic disorders and other health conditions. Gensaic is already collaborating with Novo Nordisk and is looking to partner with additional organizations to expedite its growth.
According to Erisson, the key to Gensaic’s success lies in their delivery technology, which, combined with advanced therapies like RNA interference (RNAi), has the potential to significantly advance health treatments. “RNA has become a clinical-grade commodity that we know is safe,” Erisson states, highlighting its synthesizability and specificity.
Erisson’s background includes experience in drug development at Teva Pharmaceuticals, where he took multiple drug programs into clinical development before pursuing an MBA at MIT. His interactions with Hsu and Tsedev during his time at MIT culminated in the founding of Gensaic in late 2021. The team focused on commercializing their technology after identifying innovative avenues for RNA drug delivery.
Using a technique called unbiased directed evolution, Gensaic aims to identify optimal protein scaffolds that facilitate targeted drug delivery. This method enables different species of proteins to compete for specific functions in reaching target cells. The company has already screened over 500 billion proteins through its platform, named FORGE (Functional Optimization by Recursive Genetic Evolution).
Initially focusing on gene therapies, Gensaic has shifted its attention to delivering small interfering RNA (siRNA) and other RNA modalities, particularly in tissues beyond the liver. Their technology can carry multiple RNA molecules simultaneously, providing healthcare professionals with a more versatile toolkit to combat diseases.
Unlocking New Therapeutic Opportunities
The founders believe that their innovative approach can unlock significant therapeutic potentials. By targeting specific tissues, especially the brain and adipose tissues, Gensaic hopes to enhance treatment efficacy while minimizing side effects. “We’re the only company, to my knowledge, that has a protein-based delivery mechanism to get to adipose tissue,” Erisson asserts.
This targeted delivery could aid in developing treatments for weight management, muscle retention, and conditions like fatty liver disease. Gensaic’s strategy emphasizes multiplexed medicine, focusing on combining therapeutic mechanisms from single molecules to address multiple disease targets simultaneously.
The collaboration with Novo Nordisk, focused on cardiometabolic diseases, could amount to up to $354 million in funding for various disease targets. Erisson emphasizes that Gensaic is too small to cover all opportunities independently but is committed to providing safer and more effective medicines for patients.
In summary, Gensaic is poised to revolutionize RNA therapeutic delivery through its cutting-edge technology. By leveraging AI and directed evolution, the startup aims to enhance precision medicine and expand the horizons of contemporary healthcare.
The content above is a summary. For more details, see the source article.